Bioparticle Microarrays for Chemotactic and Molecular Analysis of Human Neutrophil Swarming in vitro
--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE60544R1
Full Title:	Bioparticle Microarrays for Chemotactic and Molecular Analysis of Human Neutrophil Swarming in vitro
Section/Category:	JoVE Bioengineering
Keywords:	Microarray, microstamping, cell migration, neutrophil, swarming, proteins
Corresponding Author:	Eduardo Reategui, Ph.D. Ohio State University Columbus, OH UNITED STATES
Corresponding Author's Institution:	Ohio State University
Corresponding Author E-Mail:	reategui.8@osu.edu
Order of Authors:	Eduardo Reategui, Ph.D.
	Nicole Walters
Additional Information:	
Question	**Response**
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US$2,400)
Please indicate the **city, state/province, and country** where this article will be **filmed**. Please do not use abbreviations.	Columbus, Ohio/US

THE OHIO STATE UNIVERSITY

William G. Lowrie Department of Chemical and Biomolecular Engineering

457 Koffolt Laboratories, CBEC
151 West Woodruff Avenue
Columbus, OH 43210-1350

614-688-1410 Phone
614-292-3769 Fax

August 29th, 2019

Dear Editor,

     We are resubmitting our manuscript entitled "Bioparticle Microarrays for Chemotactic and Molecular Analysis of Neutrophil Swarming in vitro." We have extensively edited following the comments and suggestions of the different reviewers. Please do not hesitate to contact us if you require further information. We look forward to your review of our resubmission. Sincerely,

Sincerely,

E. Reátegui

Eduardo Reátegui, PhD
Assistant Professor
The Ohio State University
William G. Lowrie Department of Chemical and Biomolecular Engineering
457 Koffolt Laboratories, 151 West Woodruff, Columbus, OH 43210
614-688-1410 Office / 614-292-3769 Fax
reategui.8@osu.edu www.cbe.osu.edu

1 **TITLE:**
2 **Bioparticle Microarrays for Chemotactic and Molecular Analysis of Human Neutrophil**
3 **Swarming in vitro**
4
5 **AUTHORS AND AFFILIATIONS:**
6 Nicole Walters[1], Eduardo Reátegui[1,2]
7 [1]William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State
8 University, Columbus, OH
9 [2]Comprehensive Cancer Center, The Ohio State University, Columbus, OH
10
11 **Corresponding Author:**
12 Eduardo Reátegui   (reategui.8@osu.edu)
13
14 **Email Addresses of Co-author:**
15 Nicole Walters   (walters.660@osu.edu)
16
17 **KEYWORDS:**
18 microarray, microstamping, cell migration, neutrophil, swarming, proteins
19
20 **SUMMARY:**
21 This protocol generates bioparticle microarrays that provide spatially controlled neutrophil
22 swarming. It provides easy access to the mediators that neutrophils release during migration and
23 allows for quantitative imaging analysis.
24
25 **ABSTRACT:**
26 Neutrophil swarming is a cooperative process by which neutrophils seal off a site of infection and
27 promote tissue reorganization. Swarming has classically been studied in vivo in animal models
28 showing characteristic patterns of cell migration. However, in vivo models have several
29 limitations, including intercellular mediators that are difficult to access and analyze, as well as
30 the inability to directly analyze human neutrophils. Because of these limitations, there is a need
31 for an in vitro platform that studies swarming with human neutrophils and provides easy access
32 to the molecular signals generated during swarming. Here, a multistep microstamping process is
33 used to generate a bioparticle microarray that stimulates swarming by mimicking an in vivo
34 infection. The bioparticle microarray induces neutrophils to swarm in a controlled and stable
35 manner. On the microarray, neutrophils increase in speed and form stable swarms around
36 bioparticle clusters. Additionally, supernatant generated by the neutrophils was analyzed and 16
37 proteins were discovered to have been differentially expressed over the course of swarming. This
38 in vitro swarming platform facilitates direct analysis of neutrophil migration and protein release
39 in a reproducible, spatially controlled manner.
40
41 **INTRODUCTION:**
42 Neutrophils, the most abundant white blood cell in the bloodstream[1], are gaining attention as
43 potential diagnostic and therapeutic targets[2,3] because they may be involved in a variety of
44 medical conditions including gout[4], sepsis[3], trauma[5,6], cancer[1,7,8], and various autoimmune

45 diseases[5,9]. Neutrophil swarming is a multistage, tightly regulated process with a complexity that
46 makes it a particularly interesting focus of study[5,10,11]. During swarming, neutrophils isolate a site
47 of inflammation from the surrounding healthy tissue[5,10,11]. Proper regulation of neutrophil
48 swarming is essential to promote wound healing and ultimately inflammation resolution[5,12].
49 Neutrophil swarming has primarily been studied in vivo in rodent[12–15] and zebrafish[10–12,15]
50 models. However, the nature of these in vivo animal models gives rise to limitations[5]. For
51 example, the mediators released by neutrophils during swarming are not easily accessible for
52 analysis[5]. Additionally, there are many potential sources for a given mediator in vivo, so an in vivo
53 experiment must introduce a genetic deficiency to inhibit cellular production and/or interaction
54 in order to investigate the role of that mediator in a given process[13]. An in vitro experiment
55 circumvents this complication by enabling neutrophil observation without the context of
56 additional cells. Additionally, research describing human neutrophil coordinated migration is
57 limited[16]. On an in vitro swarming platform, human neutrophils can be directly analyzed. An in
58 vitro swarming platform could expand upon the knowledge gained from in vivo studies by
59 providing opportunities to fill the gaps left by the limitations of in vivo studies.
60
61 To address the need for an in vitro platform that mimics in vivo neutrophil swarming, we
62 developed a microstamping platform that enables us to pattern bioparticle microarrays that
63 stimulate neutrophil swarming in a spatially controlled manner. We generate bioparticle
64 microarrays on glass slides in a two-step process. First, we use microstamping to generate a
65 microarray of cationic polyelectrolyte (CP) spots. Second, we add a solution of bioparticles that
66 adhere to the CP spots via electrostatic interaction. By first patterning the CP layer, we can
67 selectively pattern negatively charged bioparticles to generate the desired neutrophil swarming
68 pattern. The positively charged layer holds the negatively charged bioparticles through the
69 vigorous washing step that removes the bioparticles from the areas on the glass slide that do not
70 have the CP. Additionally, the CP used here, a copolymer of acrylamide and quaternized cationic
71 monomer, is biocompatible, so it does not induce a response from the neutrophils. It has a very
72 high surface charge that immobilizes the micron-sized bioparticles to the glass slide, thus
73 inhibiting neutrophils from removing the particles from the patterned position on the glass slide.
74 This results in bioparticle clusters arranged in a microarray. When we added neutrophils to the
75 microarray, they formed stable swarms around the bioparticle clusters. Through tracking
76 neutrophil migration, we found that swarming neutrophils actively migrate toward the
77 bioparticle clusters. Furthermore, we used this platform to analyze certain mediators that
78 neutrophils release during swarming. We found 16 mediators that are differentially expressed
79 during swarming. Their concentrations follow three general trends over time: increase, decrease,
80 or spike. Our in vitro neutrophil swarming platform facilitates the analysis of spatially controlled
81 human neutrophil swarming, as well as the collection and analysis of mediators released by
82 neutrophil swarming. In a previous publication, we demonstrated that patients with certain
83 medical conditions (trauma, autoimmune disease, and sepsis), had neutrophils that functioned
84 differently than those from healthy donors[5]. In future research studies, our platform could be
85 used to analyze neutrophil function among a variety of patient populations. This platform can
86 quantitatively analyze the complex coordination involved in neutrophil swarming. Additional
87 studies can be done to provide insight on the neutrophil function of a specific patient population
88 or neutrophil response to a pathogen of interest.

PROTOCOL:

1. Microfabrication of bioparticle microarray

1.1. Using standard photolithography procedures, generate the master silicon wafer.

1.1.1. Generate a proof of the desired design using a computer-aided design (CAD) software, then send to a photomask manufacturer to produce a chrome photomask. The design used here is 4 mm x 4 mm rectangular arrays of 30 µm diameter filled in circles with a 150 µm center-to-center spacing. This design can be modified as desired for different applications.

1.1.2. Spincoat a 40 µm thick layer of a negative photoresist onto a silicon wafer. Bake wafer at 65 °C for 5 min and 95 °C for 10 min.

1.1.3. Expose wafer to UV light through a chrome photomask with 150–160 mJ/cm^2 (**Figure 1A**).

1.1.4. Bake wafer at 65 °C for 5 min and 95 °C for 10 min. Submerge wafer in photoresist developer for 10 min and rinse with isopropyl alcohol. At this stage, the pattern should be visible on the wafer (**Figure 1B**).

1.2. Thoroughly mix a 10:1 ratio of polydimethylsiloxane prepolymer and its curing agent (i.e., 20 g of prepolymer and 2 g of curing agent) and pour the uncured polydimethylsiloxane (PDMS) mixture over the master wafer in a Petri dish (**Figure 1C**).

1.3. Vacuum treat the uncured PDMS mixture until no air bubbles are present over the master wafer. Cure at 65 °C overnight.

1.4. Use a scalpel to cut around the exterior of the patterned section of the wafer, and slowly remove the cured PDMS slab. Place the PDMS slab on a clean cutting board with the patterned side facing up (**Figure 1D**).

1.5. Punch out individual stamps from the PDMS slab with an 8 mm biopsy punch (**Figure 1E**). For one glass slide, eight stamps will be needed.

1.6. Place each stamp face down on the adhesive tape to remove any debris.

1.7. In advance, prepare a 1.6 mg/mL solution of CP in water.

133 1.7.1. Add the proper amount of the CP powder to water (e.g., 0.8 g to 500 mL).

134

135 1.7.2. Mix on a stir plate at room temperature overnight, or until all the solid is dissolved into the
136 water. The CP solution can be stored at room temperature for 6 months.

137

138 1.7.3. If desired, make the CP solution fluorescent by adding poly-L-lysine labelled with
139 fluorescein isothiocyanate (PLL-FITC).

140

141 1.7.3.1. Aliquot about 10 mL of the CP solution. Add a small amount of PLL-FITC (0.05 mg) to the
142 aliquoted volume. The amount can be altered to adjust the brightness of fluorescence as desired.

143

144 1.7.3.2. Vortex the CP solution labeled with FITC for 20 s, or until the solution is a uniform, pale
145 yellow color. Protect from light and store at 4 °C for up to 1 month.

146

147 1.8. With the stamps face-up, prime each stamp with 100 µL of 1.6 mg/mL solution of CP,
148 ensuring no air bubbles form between the CP solution and the stamp (**Figure 1F**).

149

150 1.9. Invert the stamps onto a layer of CP solution (**Figure 1G**).

151

152 1.10. Remove the stamps from the CP solution after 1 h.

153

154 1.11. Dab each wet stamp face down onto a clean glass slide 6–8x to remove excess liquid.

155

156 1.12. Vacuum treat the stamps for 1–2 min.

157

158 1.13. Adhere an eight well, 9 mm diameter imaging spacer on the top of a clean glass slide as a
159 guide for stamp placement. With this spacer, each glass slide can have eight microarrays.

160

161 1.14. Place a stamp face down on the glass slide in the center of each well of the imaging spacer
162 (i.e., use eight stamps total).

163

164 1.15. Place a 5.6 ± 0.1 g balanced weight on top of each stamp and allow 10 min for stamping
165 (**Figure 1H**). A balanced weight is required to ensure the stamp is pressed evenly onto the glass
166 slide and promote even transfer of the CP to the glass slide.

167

168 1.16. Remove the weights and stamps from the glass slide (**Figure 1I**). Allow the CP layer to dry
169 at room temperature for 24 h before adding the bioparticles, as described in step 1.17. If the CP
170 is tagged with FITC, the effectiveness of the stamping can be checked at this point with a
171 fluorescent microscope at 488 nm before proceeding to step 1.17 (**Figure 1M**).

172

173 1.17. Cut a blank PDMS slab to the size of the imaging spacer and use the 8 mm biopsy punch to
174 create wells in the PDMS that align with the wells of an imaging spacer. Adhere the PDMS slab to
175 the glass slide with the imaging spacer (**Figure 1J**).

176

177 1.18. Thaw a solution of bioparticles (e.g., *E. coli* or zymosan) and dilute to 500 µg/mL in water
178 for injection (WFI).
179
180 NOTE: The bioparticles do not need to be opsonized. Neutrophil surface receptors directly
181 recognize molecules on these bioparticles[19–21].
182
183 1.19. Add 100 µL of bioparticle solution to each PDMS well on the glass slide (**Figure 1K**).
184
185 1.20. Rock the glass slide for 30 min.
186
187 1.21. Rinse the wells thoroughly with water. The bioparticle microarray can be stored in a dust-
188 free environment at 4 °C for up to 3 months. At this point, the pattern should be checked with a
189 fluorescent microscope at 594 nm before proceeding to step 2.1 (**Figure 1N**).
190
191 **2. Sample Preparation**
192
193 2.1. Collect at least 2 mL of fresh blood in K2-EDTA tubes from the desired donor. The expected
194 yield of neutrophils is 1–2 x 10^6 cells/1 mL whole blood. The imaging assay requires approximately
195 1.5 x 10^5 neutrophils, and the analysis of the supernatant requires 1 x 10^6 neutrophils. Use the
196 blood within 4 h.
197
198 2.2. Separate red blood cells (RBCs) by adding an erythrocyte aggregation agent in a 1:5 ratio to
199 the whole blood. Wait 45 min for a translucent layer (buffy coat) to separate from the layer of
200 RBCs.
201
202 2.3. Remove the buffy coat and wash with phosphate buffered saline (PBS) using 1 mL buffy coat:
203 9 mL PBS.
204
205 2.4. Centrifuge for 5 min at 190 x g and 20 °C.
206
207 2.5. Aspirate the supernatant and resuspend the pellet at 5 x 10^7 cells/mL.
208
209 2.6. Use a negative immunomagnetic selection kit to isolate neutrophils.
210
211 2.6.1. Add 50 µL of antibody cocktail/1 mL cell suspension. Wait 10 min.
212
213 2.6.2. Add 100 µL of magnetic beads/1 mL cell suspension. Wait 10 min.
214
215 2.6.3. Add cell suspension to a round-bottom tube and place in a cylindrical magnet. Wait 10 min.
216
217 2.7. Pour supernatant into a centrifuge tube. Add up to 10 mL of PBS. Centrifuge for 5 min at 190
218 x g and 20 °C.
219
220 2.8. Aspirate supernatant. Resuspend white pellet in IMDM with 0.4% human serum albumin.

221

2.9. Stain nuclei with 20 μg/mL Hoechst 33342 for 10 min at 37 °C.

224
225

2.10. Add 5 mL of IMDM with 0.4% human serum albumin to rinse. Centrifuge for 5 min at 190 x g and 20 °C.

227

2.11. Resuspend cells at 7.5×10^5 cells/mL in IMDM with 0.4% human serum albumin.

229
230
231

2.12. Add 100 μL of the cell suspension to a PDMS well containing a bioparticle microarray. Ensure the cell suspension is convex over the top of the PDMS well and does not contain any bubbles.

233
234
235

2.13. Seal with a 12 mm diameter coverslip. Cover the opening of the PDMS well with a 12 mm diameter coverslip. Press down gently onto the coverslip with tweezers so the excess cell suspension escapes to the edge of the well. Use a tissue to remove the excess cell suspension.

3. Running the assay and image analysis

239
240

3.1. Load microparticle array with cells on the live cell imaging station with a microscope equipped with a cage incubator set to 37 °C, 5% CO_2, and 90% relative humidity.

242
243
244

3.2. Use time-lapse fluorescent and brightfield microscopy to record images at 10x magnification every 10 s at 405 nm, 594 nm, and brightfield. In a typical experiment, images are collected up to 2 h.

246
247

3.3. Use an automated cell tracking software to track the migration of individual neutrophils toward the bioparticle cluster.

249
250
251

3.3.1. Use the autoregression mode of a spot detection cell tracking software. Set the spot radius to 5 μm (the approximate size of a neutrophil nucleus). Set the minimum track length to 120 s and a maximum gap size of one frame.

253
254
255

3.3.2. From the data generated by the cell tracking software, extract the files that contain the neutrophil position and speed. These files can be used with a graphing software to generate neutrophil migration tracks (**Figure 2C**) and a heat map of speed vs. time (**Figure 2D**), respectively.

257
258

3.4. Use the 405 nm fluorescent images to track swarm size over time on an image analysis software of your choice.

260
261

3.4.1. Define regions of interest (ROIs) around each bioparticle cluster where neutrophils will swarm. Keep the same size ROI to analyze each bioparticle cluster.

263

3.4.2. Analyze the mean fluorescent intensity of the 405 nm images within each ROI over time.

264

265   3.4.3. Generate a calibration curve of mean fluorescent intensity to swarm size by taking manual
266   measurements at various swarm sizes from 0 μm^2 to the maximum swarm size. Use this
267   calibration to calculate the swarm size over time.
268
269   **4. Supernatant collection and protein detection**
270
271   4.1. Incubate the neutrophils in the wells containing the bioparticle microarray at 37 °C and 5%
272   CO_2 for 3 h. Take samples at desired time points. Typically, samples will be taken at 0, 0.5, 1, and
273   3 h. To overcome the limit of detection of the protein array assay, the entire volume of
274   supernatant of a single well (200 µL) was used for each time point. Each time point was analyzed
275   in triplicate.
276
277   4.2. Using a brightfield microscope, verify that swarms are formed on the microarray.
278
279   4.3. Aspirate the supernatant with a 200 µL pipette and load in a 0.45 µm centrifuge filter tube.
280
281   4.4. Centrifuge the supernatant at 190 x g and 20 °C for 5 min and collect the filtrated volume.
282
283   4.5. Store samples at -80 °C until the processing time.
284
285   4.6. Use a microarray kit that detects a range of human proteins to process samples.
286
287   4.6.1. Add 200 µL of each sample to a separate dialysis tube provided with the kit.
288
289   4.6.2. Place the dialysis tubes in a beaker containing at least 500 mL of PBS (pH = 8.0). Stir gently
290   on a stir plate for at least 3 h at 4 °C. Change the PBS in the beaker and repeat this step.
291
292   4.6.3. Transfer each sample to a clean centrifuge tube and centrifuge at 9,000 x g for 5 min to
293   remove any precipitates. Transfer each supernatant to a clean tube.
294
295   4.6.4. Biotinylate each sample by adding 36 µL of 1x labeling reagent from the kit per 1 mg of
296   total protein in the dialyzed sample to 180 µL of dialyzed sample. Incubate at 20 °C for 30 min.
297   Mix gently every 5 min.
298
299   4.6.5. Add 3 µL of stop solution provided with the kit into each sample tube. Transfer each sample
300   to a fresh dialysis tube and repeat steps 4.6.2–4.6.3. At this stage, the sample can be stored at -
301   20 °C or -80 °C until you are ready to proceed.
302
303   4.6.6. The glass slide provided with the kit is stored at -20 °C. Allow it to come to room
304   temperature. Place the assembled glass slide in a laminar flow hood for 1–2 h at room
305   temperature.
306
307   4.6.7. Add 400 µL of the blocking buffer provided with the kit into each well of the assembled
308   glass slide. Incubate at room temperature for 30 min.

309

310   4.6.8. Centrifuge the prepared samples for 5 min at 9,000 x g to remove precipitates or
311   particulates. Dilute 5x with blocking buffer.

312

313   4.6.9. Remove the blocking buffer from each well. Add 400 μL of the diluted samples into the
314   appropriate wells. Incubate for 2 h at room temperature while rocking.

315

316   4.6.10. Decant the samples from each well. Wash 3x with 800 μL of the 1x wash buffer I provided
317   with the kit at room temperature for 5 min each while rocking.

318

319   4.6.11. In a clean container, submerge the assembled glass slide in 1x wash buffer I. Wash 2x at
320   room temperature for 5 min each while rocking.

321

322   4.6.12. Add 400 μL of 1x Cy3-conjugated streptavidin to each sub-array. Cover with plastic
323   adhesive strips. Protect from light for the remainder of the protocol.

324

325   4.6.13. Incubate for 2 h at room temperature while rocking.

326

327   4.6.14. Decant the solution and disassemble the glass slide from the sample chambers.

328

329   4.6.15. In the 30 mL centrifuge tube provided with the kit, carefully add the glass slide and
330   enough 1x wash buffer I to cover the glass slide. Wash 3x for 10 min each at room temperature
331   while rocking.

332

333   4.6.16. In the 30 mL centrifuge tube, wash 2x with 1x wash buffer II for 5 min each at room
334   temperature while rocking.

335

336   4.6.17. Wash the glass slide with 30 mL of ddH$_2$O for 5 min. Remove the glass slide from the
337   centrifuge tube and allow to dry for 20 min in a laminar flow hood. The prepared glass slide may
338   be stored at -20 °C until ready to scan.

339

340   4.6.18. Scan the glass slide with a microarray scanner at a fluorescence emission of 555 nm.

341

342   **REPRESENTATIVE RESULTS:**
343   When neutrophils are added to the bioparticle microarray, neutrophils that contact the
344   bioparticle clusters become activated and initiate the swarming response. The bioparticle
345   microarray was validated using time-lapse fluorescent microscopy to track neutrophil migration
346   toward the bioparticle clusters (**Video S1**). The migration of individual neutrophil nuclei is tracked
347   as they migrate toward the bioparticle cluster. When neutrophils reach the bioparticle cluster,
348   their nuclei overlap with other nuclei in the cluster. Thus, it is not possible to accurately track a
349   neutrophil within the cluster using this method. Zymosan and *E. coli* bioparticle clusters both
350   result in the generation of neutrophil swarms. For our results, **Figure 2B** uses data from
351   neutrophil swarms generated by *E. coli* particles. **Figure 3** and the other panels of **Figure 2** use
352   neutrophil swarms generated by zymosan particles. The results obtained demonstrate that

353 bioparticle clusters stimulates neutrophil activation when a neutrophil contacted the cluster,
354 which ultimately led to the formation of stable neutrophil swarms around each cluster after 3–
355 60 min (**Figure 2A, top**). In contrast, neutrophils did not show collective migration in the absence
356 of bioparticle clusters (**Figure 2A**, bottom, and **Video S2**). Using the fluorescent intensity of
357 stained neutrophil nuclei at 405 nm, the average neutrophil swarm size around 30 μm diameter
358 *E. coli* bioparticle clusters was found to be 1,490 ± 680 μm^2 (mean ± SD, **Figure 2B**, top). The
359 fluorescence intensity of a given region of interest where no bioparticle clusters are present was
360 approximately constant over time, which confirmed the absence of collective migration in this
361 setting (**Figure 2B**, bottom). Tracks of neutrophil migration show that neutrophils converged on
362 a bioparticle cluster when one was present (**Figure 2C**, top). Conversely, no convergence was
363 observed in the control system (**Figure 2C**, bottom). The speed (distance travelled/time) of
364 swarming and nonactivated neutrophils was measured and a statistically significant difference in
365 the speed distributions was found (ANOVA, *p* < 0.0001), as shown in **Figure 2D**. The average
366 speed for swarming neutrophils was 20.6 ± 13.0 μm/min (mean ± SD), and the average speed for
367 control neutrophils was 2.0 ± 2.2 μm/min.
368
369 Additionally, the concentration of 16 proteins that neutrophils released during swarming were
370 analyzed (**Figure 3**). The normalized concentration of each protein at different time points in the
371 swarming process (t = 0, 0.5, 1, and 3 h) were calculated, where the normalized concentration is
372 ($C - C_{min}$) / ($C_{max} - C_{min}$). 10 proteins increased in concentration throughout swarming. These
373 proteins were adipsin, galectin-3, GROa, IL-6R, MIP-1a, MMP-8, MMP-9, Nidogen-1, TIMP-1, and
374 TLR2. Two proteins (pentraxin 3 and RANK) decreased in concentration throughout swarming.
375 The remaining four proteins (clusterin, PF4, RANTES, and Trappin-2) increased during the first
376 hour of swarming but decreased thereafter. In other words, the concentrations of those proteins
377 "spiked" during swarming. Of the 16 proteins identified, 12 proteins were identified in our
378 previous publication[5]. Adipsin, galectin-3, nidogen-1, pentraxin 3, TIMP-1, and TLR2 were shown
379 to be swarming-specific, while clusterin, IL-6R, MMP-8, and MMP-9, RANK, and trappin-2 were
380 not[5].
381
382 **FIGURE LEGENDS:**
383 **Figure 1. Production of bioparticle microarray.** A silicon wafer coated with negative photoresist
384 is exposed to UV light through a chrome photomask (**A**). After the silicon wafer is baked and
385 developed, a photoresist pattern remains on the surface of the silicon wafer. This is the master
386 wafer (**B**). In a Petri dish, a PDMS mixture is added to the top of the master wafer. The PDMS is
387 cured overnight at 65 °C to form the PDMS mold (**C**). The PDMS mold is cut from the master wafer
388 and a biopsy punch is used to punch out individual PDMS stamps (**D**). A PDMS stamp (**E**) is coated
389 with CP solution (**F**). The stamp is inverted onto a thin layer of CP solution (**G**). After incubating
390 in the CP solution for 1 h, the stamp is blotted onto a glass slide to remove excess CP. Eight stamps
391 are then pressed onto a clean glass slide with a 5.6 ± 0.1 g weight, aligned with an imaging spacer
392 (**H**). When the stamp is removed, a CP pattern remains (**I**). A PDMS slab with precut wells is
393 adhered to the glass slide (**J**). Then, a bioparticle solution is added over the CP pattern (**K**). The
394 negatively charged bioparticles bind to the positively charged polyelectrolyte via electrostatic
395 interaction. The excess bioparticle solution is washed away, leaving bioparticles patterned on top
396 of the CP pattern (**L**). (**M**) Fluorescent image of the CP layer labeled with FITC (Scale bars = 50 μm,

397 large image; Scale bar = 25 μm, inset). (**N**) Fluorescent image of patterned zymosan bioparticles
398 conjugated with Texas Red (Scale bar = 100 μm, large image; Scale bar = 50 μm, inset).
399
400 **Figure 2. Neutrophil swarm growth around bioparticle clusters.** In the presence of bioparticle
401 clusters, neutrophils undergo collective migration toward the bioparticle clusters (bottom,
402 control neutrophils). When no bioparticles are present, the neutrophils do not perform
403 collective migration. (**A**) In the presence of zymosan bioparticle clusters, neutrophils form
404 swarms in 30 min. Without bioparticle clusters, no swarms form (Scale bars = 50 μm). (**B**)
405 Neutrophil swarms grow to an average size of 1,490 ± 680 μm^2 (mean ± SD) around 30 μm
406 diameter *E. coli* bioparticle clusters. Control neutrophils exhibit a constant density that
407 corresponds to no swarm growth (ANOVA, $p < 0.0001$, n = 32 neutrophil swarms, N = 1 donor,
408 error bars = standard deviation). (**C**) Tracks of swarming neutrophils converge on the zymosan
409 bioparticle clusters, while control neutrophils show no converging point (Scale bars = 50 μm).
410 (**D**) Neutrophils swarming toward a zymosan target have a mean speed of 20.6 ± 13.0 μm/min
411 (mean ± SD), while control neutrophils have a mean speed of 2.0 ± 2.2 μm/min. Each count on
412 the heat map represents a neutrophil with the given instantaneous speed at the given time
413 point. These heat maps are representative of one experiment (n = 1 swarm; N = 1 donor;
414 ANOVA, 6,114 = swarming neutrophils, 32,116 = control neutrophils, $p < 0.0001$).
415
416 **Figure 3. Free mediators released by swarming neutrophils.** Neutrophil swarming affects the
417 production of various proteins over time. Protein concentration was measured at 0, 0.5, 1, and 3
418 h. The data points were fitted with smoothing splines (λ = 0.05). These proteins tend to follow
419 one of three characteristic trends: decreasing over time, increasing over time, or spiking around
420 1 h and then decreasing (Error bars = standard deviation; n = 3 replicates; N = 1 donor).
421
422 **Video S1. Neutrophil swarming toward zymosan bioparticle clusters.** Neutrophil nuclei are
423 shown in blue. Zymosan targets are marked with red circles (Scale bar = 50 μm; original
424 acquisition time = 60 min).
425
426 **Video S2. Nonactivated neutrophil random migration.** Neutrophil nuclei are shown in blue
427 (Scale bar = 50 μm; original acquisition time = 60 min).
428
429 **DISCUSSION:**
430 We developed a microstamping platform to generate uniform arrays of bioparticles to stimulate
431 in vitro neutrophil swarming. The in vitro nature of our platform allows us to circumvent the
432 complications that arise with in vivo swarming experiments, namely the poor ability to analyze
433 mediators released by swarming neutrophils[5]. Additionally, in vivo models are typically
434 performed in rodents[11–13,15,22,23] or zebrafish[11,12,15,23]. Our platform uses human neutrophils,
435 which enables us to more directly interpret our results in the context of human disease, though
436 certain similarities between mouse and human neutrophils have been observed[5,11]. Additionally,
437 we maintain a spatially-controlled swarming environment that distinguishes our platform from
438 in vivo models by providing a high level of reproducibility that facilitates the analysis of human
439 neutrophil collective migration as well as the collection and analysis of mediators released by
440 swarming neutrophils.

441

442 During the development of our microstamping protocol, several challenges arose that required
443 careful troubleshooting. First, the CP used for the microstamping is highly hydrophilic, and the
444 PDMS stamps are hydrophobic. Because the CP does not have a high affinity for PDMS, our
445 procedure was carefully designed to avoid the formation of bubbles and promote wetting. By
446 first priming the stamp with CP while face-up (step 1.8), we minimize the formation of bubbles
447 between the CP and the stamp. The stamp is then inverted onto a layer of CP and incubated for
448 1 h. This long incubation time ensures that every section of the stamp is wetted. Second, the
449 process of removing excess CP before stamping on a clean glass slide (step 1.11) can be
450 inconsistent. While performing step 1.11, the stamp must be carefully examined. When the
451 pattern begins to become visible, the stamp is ready for step 1.12. Additionally, the required
452 vacuum time to dry the stamps (step 1.12) can vary. This is primarily dependent on the weather.
453 On a warm, humid day, 2 min of vacuum time is required. On a cool, dry day, 1 min of vacuum
454 time is sufficient.

455

456 We have shown that neutrophils from healthy donors form stable swarms around bioparticle
457 clusters. With time-lapse fluorescent microscopy, we can quantify swarm size and track
458 neutrophil migration, which enables us to analyze neutrophil chemotaxis quantitatively[5]. For
459 example, we have previously shown that this platform can be used to calculate the chemotactic
460 index (CI, the cosine of the angle between the neutrophil velocity vector and the position vector
461 between the neutrophil and the nearest bioparticle cluster), speed (distance the neutrophil
462 travels divided by time), radial velocity (the speed multiplied by CI), and the total distance
463 traveled (the difference between initial and final neutrophil position) of individual migrating
464 neutrophils[5]. Unlike most in vitro studies[24–26], our platform does not have an artificial
465 chemotactic gradient, so neutrophil intercellular communication is the sole driving force of
466 neutrophil migration. Additionally, the supernatant generated by swarming neutrophils is easily
467 accessible. We can collect and analyze the supernatant for intercellular mediators released by
468 neutrophils without interference from other cell types that are present in vivo. 16 proteins were
469 observed whose expression during swarming could be described as one of three trends: increase
470 (10 proteins), decrease (two proteins), and spike (four proteins). Six of these proteins confirmed
471 previously reported trends during swarming over time[5]. Some of the identified proteins were
472 previously shown to be swarming-specific, while others were expressed differentially by
473 activated non-swarming neutrophils[5]. Proteins that increase in concentration over time are likely
474 associated with the pro-inflammation response. Some of the proteins that increase in
475 concentration over time are already known to be involved in the pro-inflammatory response
476 (e.g., galectin-3 and MMP-9)[27,28]. The relationship between other proteins and inflammation is
477 less well understood. The proteins that spike or decrease during swarming may be involved in
478 the regulation of inflammation. However, further research is necessary to understand the role in
479 inflammation of many of the proteins that are differentially expressed during swarming.
480 Analyzing released mediators along with neutrophil migration can help us better understand the
481 complex picture of inflammation and how neutrophils impact the surrounding tissue during
482 swarming.

483

484 In future studies, our platform can be used to thoroughly study the ability of unhealthy

neutrophils to generate stable swarms around patterned bioparticle clusters. Various medical conditions have been related to neutrophils, including sepsis[3], trauma[6], and cancer[1,8,17,18], which suggests neutrophils in these patients may have altered function. This platform can be used to examine differences between the intercellular mediators released by healthy and unhealthy neutrophils. Additionally, this platform could be modified to pattern live microbes and used to analyze neutrophil response to live microbes in vitro.

In conclusion, we have developed a novel platform for analyzing neutrophil swarming in vitro. The highly controlled nature of our platform allows us to mitigate issues that arise during in vivo neutrophil swarming experiments. Neutrophil swarming on a bioparticle microarray is easily quantifiable via time-lapse fluorescent microscopy. Additionally, we can collect the mediators released by the neutrophils without the interference of other tissues that are present in vivo. This platform can be used in future research to quantify differences between the migration behaviors of neutrophils from healthy and unhealthy donors.

DISCLOSURES:
The authors declare no conflicts of interest.

REFERENCES:
1. Coffelt, S. B., Wellenstein, M. D., de Visser, K. E. Neutrophils in cancer: neutral no more. *Nature Reviews Cancer*. **16** (7), 431–446 (2016).
2. Jones, C. N. et al. Microfluidic Platform for Measuring Neutrophil Chemotaxis from Unprocessed Whole Blood. *Journal of Visualized Experiments*. (88), 1–6 (2014).
3. Ellett, F. et al. Diagnosis of sepsis from a drop of blood by measurement of spontaneous neutrophil motility in a microfluidic assay. *Nature Biomedical Engineering*. **2** (April), 207–214 (2018).
4. Malawista, S. E., Chevance de Boisfleury, A., Naccache, P. H. Inflammatory Gout: Observations over a Half-Century. *The FASEB Journal*. **25** (12), 4073–4078 (2011).
5. Reátegui, E. et al. Microscale arrays for the profiling of start and stop signals coordinating human-neutrophil swarming. *Nature Biomedical Engineering*. **1** (7), 1–12 (2017).
6. Morgan, A. S. Risk factors for infection in the trauma patient. *Journal of the National Medical Association*. **84** (12), 1019–23 (1992).
7. Szczerba, B. M. et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. *Nature*. **566**, 553–557 (2019).
8. Treffers, L. W., Hiemstra, I. H., Kuijpers, T. W., van den Berg, T. K., Matlung, H. L. Neutrophils in cancer. *Immunological Reviews*. **273**, 312–328 (2016).
9. Grayson, P. C., Kaplan, M. J. At the Bench: Neutrophil extracellular traps (NETs) highlight

529 novel aspects of innate immune system involvement in autoimmune diseases. *Journal of*
530 *Leukocyte Biology*. **99** (2), 253–264 (2016).

531 10. Lämmermann, T. In the eye of the neutrophil swarm--navigation signals that bring
532 neutrophils together in inflamed and infected tissues. *Journal of Leukocyte Biology*. **100**
533 (1), 55–63 (2016).

534 11. Kienle, K., Lämmermann, T. Neutrophil swarming: an essential process of the neutrophil
535 tissue response. *Immunological Reviews*. **273** (1), 76–93 (2016).

536 12. de Oliveira, S., Rosowski, E. E., Huttenlocher, A. Neutrophil migration in infection and
537 wound repair: going forward in reverse. *Nature Reviews Immunology*. **16** (6), 378–391
538 (2016).

539 13. Lämmermann, T. et al. Neutrophil swarms require LTB4 and integrins at sites of cell death
540 in vivo. *Nature*. **498** (7454), 371–375 (2013).

541 14. Kreisel, D. et al. In vivo two-photon imaging reveals monocyte-dependent neutrophil
542 extravasation during pulmonary inflammation. *Proceedings of the National Academy of*
543 *Sciences of the United States of America*. **107** (42), 18073–18078 (2010).

544 15. Coombes, J. L., Robey, E. A. Dynamic imaging of host-pathogen interactions in vivo. *Nature*
545 *Reviews Immunology*. **10** (5), 353–364 (2010).

546 16. Lämmermann, T. Cell migration: Arraying neutrophils in swarms. *Nature Biomedical*
547 *Engineering*. **1** (7), 1–2 (2017).

548 17. Powell, D. R., Huttenlocher, A. Neutrophils in the Tumor Microenvironment. *Trends in*
549 *Immunology*. **37** (1), 41–52 (2016).

550 18. Uribe-querol, E., Rosales, C. Neutrophils in Cancer : Two Sides of the Same Coin. *Journal of*
551 *Immunology Research*. **2015** (2015).

552 19. Underhill, D. M., Ozinsky, A. Toll-like receptors: Key mediators of microbe detection.
553 *Current Opinion in Immunology*. **14** (1), 103–110 (2002).

554 20. Netea, M. G., Van Der Meer, J. W. M., Kullberg, B. J. Recognition of fungal pathogens by
555 toll-like receptors. *Immunology of Fungal Infections*. 259–272 (2007).

556 21. Thomas, C. J., Schroder, K. Pattern recognition receptor function in neutrophils. *Trends in*
557 *Immunology*. **34** (7), 317–328 (2013).

558 22. Prince, L. R., Whyte, M. K., Sabroe, I., Parker, L. C. The role of TLRs in neutrophil activation.
559 *Current Opinion in Pharmacology*. **11** (4), 397–403 (2011).

560 23. Tan, S.-Y., Weninger, W. Neutrophil migration in inflammation: intercellular signal relay
561 and crosstalk. *Current Opinion in Immunology*. **44**, 34–42 (2017).

562 24. Menezes, G. B., Rezende, R. M., Pereira-Silva, P. E. M., Klein, A., Cara, D. C., Francischi, J.
563 N. Differential involvement of cyclooxygenase isoforms in neutrophil migration in vivo and
564 in vitro. *European Journal of Pharmacology*. **598** (1–3), 118–122 (2008).

565 25. Afonso, P. V. et al. LTB4 Is a Signal-Relay Molecule during Neutrophil Chemotaxis.
566 *Developmental Cell*. **22** (5), 1079–1091 (2012).

567 26. Gounni, A. S. et al. In Vivo Regulates Neutrophil Migration In Vitro and Chemorepellent
568 Semaphorin 3E Negatively Chemorepellent Semaphorin 3E Negatively Regulates
569 Neutrophil Migration In Vitro and In Vivo. *The Journal of Immunology*. **198**, 1023–1033
570 (2017).

571 27. Dumic, J., Dabelic, S., Flögel, M. Galectin-3: An open-ended story. *Biochimica et Biophysica*
572 *Acta - General Subjects*. **1760** (4), 616–635 (2006).

573   28.   Padmanabhan Iyer, R. et al. Matrix metalloproteinase-9-dependent mechanisms of
574   reduced contractility and increased stiffness in the aging heart. *Proteomics - Clinical*
575   *Applications*. **10** (1), 92–107 (2016).
576

Figure 1

Figure 2

Figure 3

Figure 3

Video 1

Click here to access/download
Video or Animated Figure
Supplementary_Video_1.mp4

Video 2

Click here to access/download
Video or Animated Figure
Supplementary_Video_2.mp4

Name of Reagent/ Equipment	Company	Catalog Number
"The Big Easy" EasySep Magnet	STEMCELL Technologies	18001
Cell Incubator	Okolab	777057437 / 77057343
EasySep Human Neutrophil Isolation Kit	STEMCELL Technologies	17957
Eclipse Ti2	Nikon Instruments	MEA54010 / MEF55037
Escherichia coli (K-12 strain) BioParticles Texas Red conjugate	Invitrogen	E2863
Harris Uni-Core 8-mm biopsy punch	Sigma Aldrich	Z708925
HetaSep	STEMCELL Technologies	7906
Hoechst 33342	Life Technologies	H3570
Human L1000 Array	Raybiotech Inc.	AAH-BLG-1000-4
Human Serum Albumin (HSA)	Sigma Aldrich	A5843
Iscove's Modified Dulbeccos' Medium (IMDM)	Thermo Fisher Scientific	12440053
K2-EDTA tubes	Thermo Fisher Scientific	02-657-32
Low Reflective Chrome Photomask	Front Range Photomask	N/A
Microarray Scanner	Perkin Elmer	ASCNGX00
Microscopy Image Analsysis Software - Imaris	Bitplane	9.3.0
NiS Elements Advanced Research Software Package	Nikon Instruments	MQS31100
Poly-L-lysine fluorescein isothiocyanate (PLL-FITC)	Sigma Aldrich	P3069-10MG
SecureSeal 8-well Imaging Spacer	Grace Bio-Labs	654008
Silicon Wafer	University Wafer	590
Spin Coater	Laurell	WS-650MZ-23NPPB
SU-8 2025	MicroChem	2025
SU-8 Developer	MicroChem	Y020100
Sylgard 184 (polydimethylsiloxane, PDMS)	Dow	1673921
UV Exposure Masking System	Kloé	UV-KUB 2
Water	Thermo Fisher Scientific	A1287303
Zetag 8185	BASF	8185
Zymosan A *S. cerevisiae* BioParticles Texas Red conjugate	Invitrogen	Z2843

Comments/Description

Magnet to use with neutrophil isolation kit

Okolab cage incubator for temperature and CO2 control

Kit for immunomagnetic negative selection of human neutrophils

Inverted research microscope

Bioparticle powder, dissolve in water prior to addition to Zetag® array

To cut PDMS stamps

Erythrocyte aggregation agent for separating buffy coat from red blood cells in fresh human blood

Nucleus fluorescent stain

High density array to detect 1000 human proteins

Low endotoxin HSA, to prepare 2 % solutions in IMDM for isolated neutrophils

To resuspend isolated neutrophils

Tubes for blood collection

Dimensions 5" x 5" x 0.09" (L x W x D)

Fluorescence reader of protein patterned microdomains

Software for automatic cell tracking analysis

Software for automatic live cell imaging and swarm size calculation

30,000 - 70,000 MW PLL labeled with FITC, used to fluorescently label CP solution

8-well, 9-mm diameter, adhesive imaging spacer

Silicon 100 mm N/P (100) 0- 100 ohm-cm 500 µm SSP test

Used to spincoat a 40-µm layer of photoresist onto silicon wafer

Negative photoresist to make silicon master wafer

Photoresist developer. Remove non-crosslinked SU-8 2025 from silicon wafer

2-part silicone elastomer kit for making microstamps and PDMS wells

Used to crosslink photoresist on silicon wafer through chrome mask with UV light

High quality water to dilute bioparticles

Cationic polyelectrolyte (CP), powder, Copolymer of acrylamide and quaternized cationic monomer, forms "inking solution" for micr

Bioparticle powder, dissolve in water prior to addition to Zetag array

ostamping when dissolved in water

jove

JOURNAL OF VISUALIZED EXPERIMENTS

1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Author(s):

> Bioparticle Microarrays for Chemotactic and Molecular Analysis of Neutrophil swarming in vitro
> Adcote walters, Eduardo Reategui

Item 1: The Author elects to have the Materials be made available (as described at http://www.jove.com/publish) via:

☑ Standard Access   ☐ Open Access

Item 2: Please select one of the following items:

☑ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1.   **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "**Agreement**" means this Article and Video License Agreement; "**Article**" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "**Author**" means the author who is a signatory to this Agreement; "**Collective Work**" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "**CRC License**" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode; "**Derivative Work**" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "**Institution**" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "**JoVE**" means MyJove Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; "**Materials**" means the Article and / or the Video; "**Parties**" means the Author and JoVE; "**Video**" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2.   **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3.   **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and(c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

612542.6   For questions, please contact us at submissions@jove.com or +1.617.945.9051.

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Protection of the Work. The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

jove
1 Alewife Center #200
Cambridge, MA 02140
tel 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name: Eduardo Reátegui

Department: Chemical and Biomolecular Engineering

Institution: Ohio State University

Title: Assistant Professor

Signature: E. [signature]   Date: 07/09/19

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

Responses to Reviewers

Editorial comments:

General:

Q1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

R1. We thank the editor for this comment. We have reviewed the manuscript thoroughly and edited any issues we found.

Q2. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please limit the use of commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents.
For example: Zetag®, SylgardTM, HetaSep, Nikon Ti2, RayBiotech, etc.

R2. We removed the instances of commercial language. We changed Zetag® to the generic "cationic polyelectrolyte" (CP) and HetaSep to "erythrocyte aggregation agent."

Keywords:

Q1. Please provide at least 6 key words or phrases.

R1. The key words were edited as follows: "Microarray, microstamping, cell migration, neutrophil, swarming, proteins"

Protocol:

Q1. Please include an ethics statement before the numbered protocol steps, indicating that the protocol follows the guidelines of your institution's human research ethics committee.

R1. We added the following ethics statement to the beginning of the protocol section: "**Ethics statement:** The authors acknowledge our healthy volunteers who kindly donated their blood. Blood specimens were obtained after informed volunteer consent according to institutional review board (IRB) protocol #2018H0268 reviewed by the Biomedical Sciences Committee at The Ohio State University."

Q2. For each protocol step, please ensure you answer the "how" question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action. If revisions cause a step to have more than 2-3 actions and 4 sentences per step, please split into separate steps or substeps.

R2. We have expanded many of the protocol steps to more effectively explain how to perform the steps.

Specific Protocol steps:

Q1. 4.1: Are separate microarrays used for each time point? Please clarify.

R1. Yes, the supernatant of each time point came from a different microarray. This is necessary because the concentration of the proteins is low and the volume of each well is required to achive the minimum level of detection of the protein array assay. The following text has been added to step 4.1: "To overcome the limit of detection of the protein array assay, the entire volume of supernatant of a single well (200 µL) was used for each time point."

Figures:

Q1. Figures 2 and 3: Please use 'µm' and 'µL' instead of 'um' and 'uL'.

R1. Figures 2 and 3 were corrected to use 'µm' and 'µL' instead of 'um' and 'uL'.

Q2. Figure 3: What are the fitted curved here?

R2. The curves fitted here are smoothing splines with $\lambda = 0.05$. The caption for Fig. 3 was edited for clarification: "The data points were fitted with smoothing splines ($\lambda = 0.05$)."

Discussion:

Q1. Please also discuss critical steps of the protocol and modifications/troubleshooting in the Discussion section.

R1. The following text has been added to the discussion section: "During the development of our microstamping protocol, several challenges arose that required careful troubleshooting. For instance, the CP used for the microstamping is highly hydrophilic. The PDMS stamps are hydrophobic. Since the CP does not have a high affinity for PDMS, our procedure was carefully designed to avoid the formation of bubbles and promote wetting. By first priming the stamp with CP while face-up (step 1.8), we minimize the formation of bubbles between the CP and the stamp. The stamp is then inverted onto a layer of CP and incubated for 1 h. This long incubation time ensures every section of the stamp is wetted. Second, the process of removing excess CP before stamping on a clean glass slide (step 1.11) can be inconsistent. While performing step 1.11, look closely at the stamp. When the pattern begins to become visible, the stamp is ready for step 1.12. Additionally, the required vacuum time to dry the stamps (step 1.12) can vary. This is primarily dependent on the weather. On a warm, humid day, 2 min of vacuum time is required. On a cool, dry day, 1 min of vacuum time is sufficient."

Table of Materials:
Q1. Please ensure the Table of Materials has information on all materials and equipment used, especially those mentioned in the Protocol.

R1. The Table of Materials was updated to include all materials and equipment used as mentioned in the protocol.

Reviewers' comments:
Reviewer #1:
Manuscript Summary:
The manuscript describe a method to fabricate a bioparticle microarray to study human neutrophil swarming. Neutrophil behavior as well as neutrophil derived cytokines can be studies in detail with this technique. Overall this protocol will be very useful for researchers studying neutrophil behavior and inflammation.

R. We thank the reviewer for the comments that will improve the quality of our manuscript. We have addressed all his/her comments.

Major Concerns:
none.

Minor Concerns:
Q1. It will be helpful to specify the volumes taken at step 4.1 at each time point.

R1. Step 4.1 has been edited as follows: "To overcome the limit of detection of the protein array assay, the entire volume of supernatant of a single well (200 µL) was used for each time point."

Reviewer #2:
Manuscript Summary:
Reategui and Walters describe in their manuscript an experimental method to study swarming of human neutrophils on slides with patterns of inert bioparticles in vitro. The great potential of this method was already proven by their earlier work (Reategui et al., Nat Biomed Eng. 2017) with the identification of novel regulators of neutrophil swarming. Now, the authors present an optimized protocol of their microarray assay. Here, they describe in detail how their technical platform is fabricated. In addition, they explain how the assay can

be used to obtain reproducible data about migration dynamics and mediator release of swarming neutrophils. In conclusion, the standardization and high-throughput design makes their in vitro neutrophil swarming platform an unprecedented tool and powerful alternative to in vivo swarming assays. Before considering for publication, more detailed information should be included in some parts of the protocol.

R. We thank the reviewer for the comments that will improve the quality of our manuscript. We have addressed all his/her comments.

Minor Concerns:
My main questions and suggestions for the authors are:

Introduction:
Q1. Line 62-64: The authors refer to differing neutrophil migratory behavior between species. However, human neutrophil swarming has been shown to follow the same dynamics as in mice (Refs. 11, 15) and use similar chemotactic mediators (Refs. 5, 15). Please adapt this passage. This also refers to the discussion (Lines 255-257).

R1. The passages in the introduction and the discussion were updated to reflect this. In the introduction, the passage was modified as follows: "Additionally, research describing human neutrophil coordinated migration is limited.[16] On an *in vitro* swarming platform, human neutrophils can be directly analyzed." The discussion now says: "Additionally, in vivo models are typically performed in rodents[11–13, 15, 22, 23] or zebrafish.[11, 12, 15, 23] Our platform uses human neutrophils, which enables us to more directly interpret our results in the context of human disease, though certain similarities between mouse and human neutrophils have been observed.[5, 11]".

Q2. Line 72: What is the advantage and feature of Zetag? This is nowhere explained throughout the text. Please comment on this is any part of this protocol.

R2. We removed the commercial name Zetag and replaced it with the generic "cationic polyelectrolyte" (abbreviated CP). The following explanation was added to the introduction: "By first patterning the CP layer, we are able to selectively pattern negatively charged bioparticles to generate the desired neutrophil swarming pattern. The positively charged layer holds the negatively charged bioparticles through the vigorous washing step that removes the bioparticles from the areas on the glass slide that do not have the CP. Additionally, the CP used here, a copolymer of acrylamide and quaternized cationic monomer, is biocompatible, so it does not induce a response from the neutrophils. It has a very high surface charge, which immobilizes the micron-sized bioparticles to the glass slide,

thus inhibiting neutrophils from removing the particles from the patterned position on the glass slide." (Lines 71 – 79)

Protocol:

Q1. General statement to Point 1 (Microfabrication of Bioparticle Microarray): For biologists this protocol part requires a complete visualization in the video, from start to end. Please also adapt Figure 1 with better explanations in the figure, starting with steps from 1.1.

R1. Figure one has been updated to include the microfabrication process, and in the video we will include the microfabrication of the microstamps in detail. Additionally, the following has been added to the Fig. 1 caption: "A silicon wafer coated with negative photoresist is exposed to UV light through a chrome photomask (**A**). After the silicon wafer is baked and developed, a photoresist pattern remains on the surface of the silicon wafer. This is the master wafer (**B**). In a petri dish, a PDMS mixture is added to the top of the master wafer. The PDMS is cured overnight at 65 °C to form the PDMS mold (**C**). The PDMS mold is cut from the master wafer and a biopsy punch is used to punch out individual PDMS stamps (**D**)."

Q2. Please explain the generation of the master mold silicon waver including the design of the patterns (pattern size, distance between patterns etc.) and the used equipment in more detail or refer to a protocol with a detailed description [1.1, 87].

R2. Step 1.1. was expanded as follows:

"1.1. Using standard photolithography procedures, generate the master silicon wafer.

1.1.1. Generate a proof of the desired design using a computer-aided design (CAD) software. This design can be sent to a photomask manufacturer to produce a chrome photomask. The design used here is 4 mm x 4 mm rectangular arrays of 30-µm diameter filled in circles with a 150-µm center-to-center spacing. This design can be modified as desired for different applications.

1.1.2. Spincoat a 40-µm thick layer of a negative photoresist onto a silicon wafer. Bake wafer at 65 °C for 5 min and 95 °C for 10 min.

1.1.3. Expose wafer to UV light through a chrome photomask with 150 – 160 mJ/cm^2 (**Fig. 1A**).

1.1.4. Bake wafer at 65 °C for 5 min and 95 °C for 10 min. Submerge wafer in photoresist developer for 10 min and rinse with isopropyl alcohol. At this stage, the pattern should be visible on the wafer (**Fig. 1B**)."

Q3. Please state the required volumes of polymers that need to be prepared to cover a master wafer [1.2, 91]

R3. Step 1.2 has been modified as follows: "1.2. Thoroughly mix a 10:1 ratio of polydimethylsiloxane prepolymer and its curing agent (i.e., 20 g prepolymer and 2 g curing agent) and pour the uncured polydimethylsiloxane (PDMS) mixture over the master wafer in a petri dish (**Fig. 1C**)."

Q4. Please briefly explain why the balanced weight is required [1.9, 111].

R4. Step 1.15 has been modified to explain the balanced weight. "1.14. Place a 5.6 ± 0.1 g balanced weight on top of the stamp and allow 10 min for stamping (**Figure 1D**). A balanced weight is required to ensure the stamp is pressed evenly onto the glass slide and promote even transfer of the CP to the glass slide."

Q5. Please make clear that you used 8 individual stamps per slide and not one (e.g. 1.15, 125). Be more careful with the phrasing here.

R5. Steps 1.5 – 1.15 were modified to more clearly explain that 8 stamps are used per slide. Some of the major changes were in step 1.5, "For one glass slide, 8 stamps will be needed," and steps 1.13-1.14, "1.13. Adhere an imaging spacer (8 well, 9-mm diameter) on the top of a clean glass slide as a guide for stamp placement. With this spacer, each glass slide can have 8 microarrays. 1.14 Place a stamp face down on the glass slide in the center of each well of the imaging spacer (i.e., use 8 stamps total)."

Q6. At what temperature does the drying of the Zetag® layer occur? [1.15, 125].

R6. The Zetag (cationic polyelctrolyte) dries at room temperature. Step 1.15 has been modified as follows: "1.16. Remove the weight and stamp from the glass slide (**Figure 1I**). Allow the CP layer to dry at room temperature for 24 h before adding the bioparticles (continuing with step 1.17)."

Q7. Please explain in more detail what you mean with "adding the second layer" [1.15, 125]. Do you continue with step 1.7? Please clarify this.

R7. The second layer refers to the bioparticle layer added onto the Zetag. Step 1.16 has been modified as follows: "1.16. Remove the weight and stamp from the glass slide (**Figure 1I**). Allow 1 day for the CP layer to dry at room temperature before adding the bioparticles (continuing with step 1.17)."

Q8. The addition of a blank PDMS slab to the glass slide is not visible in Figure 1f [1.16, 128-130]. The slides look the same in Fig1e and 1f. The authors should consider illustrating the whole fabrication process of the slides including the blank PDMS slab and the SecureSealTM spacer.

R8. We modified the schematic to show the addition of the PDMS slab (**Fig. 1J-L**). In addition, the following was added to the figure caption: "A PDMS slab with pre-cut wells is

adhered to the glass slide (**J**).". The following reference was added to the protocol section of the text: "1.17. Cut a blank PDMS slab to the size of the imaging spacer and use the 8-mm biopsy punch to create wells in the PDMS that align with the wells of an imaging spacer. Adhere the PDMS slab to the glass slide with the imaging spacer (**Fig. 1J**)."

Q9. In which buffer/medium should bioparticles be diluted [1.17, 132]. Do they need to be opsonized? Is this the same for both zymosan and E. coli particles (as mentioned in the Material Table)? Please clarify this.

R9. The bioparticles should be diluted in pure water. Opsonization of the particles is not necessary. Neutrophils contain receptors that are able to directly recognize molecules present on the bioparticles.[1] For example, TLR4 can recognize lipopolysaccharide (LPS), which is present on the cell membrane of gram negative bacteria like *E. coli*.[2] TLR2/TLR6 heterodimer recognizes zymosan, which is present on the cell wall of fungi.[2, 3] Here, neutrophil swarming occurs without artificial opsonization. Step 1.18 was modified as follows: "1.18. Thaw a solution of bioparticles (e.g. *E. coli* or zymosan) and dilute to 500 µg/mL in water for injection (WFI). Note: The bioparticles do not need to be opsonized. Neutrophil surface receptors directly recognize molecules on these bioparticles.[17–19]"

Q10. Which well are the authors referring to in 1.18 (line 132)?

R10. Step 1.19 was modified as follows: "1.19. Add 100 µL of bioparticle solution to each PDMS well on the glass slide (**Figure 1K**)."

Q11. Please give an approximate volume of blood / number of isolated neutrophils that should be used with the described assay [2.1, 143].

R11. Step 2.1 was modified as follows: "2.1. Collect at least 2 mL fresh blood from the desired donor in K2-EDTA tubes. The expected yield of neutrophils is 1-2 million cells / mL whole blood. The imaging assay requires approximately 0.15 million neutrophils, and the analysis of the supernatant requires 1 million neutrophils. Use the blood within 4 hours."

Q12. At which temperature should the centrifugation take place [2.4, 150]. Also [2.10, 171]. Also [4.4, 212].

R12. All centrifugation steps take place at room temperature (20 °C). Steps 2.4, 2.7, 2.10, and 4.4 were edited to reflect this.

Q13. Please refer to the concentration and not dilution factor of Hoechst 33342 [2.9, 168].

R13. Step 2.9 was modified as follows: "2.9. Stain nuclei with 20 µg/mL Hoechst 33342 for 10 min at 37 °C."

Q14. Please illustrate the sealing with a coverslip in more detail [2.12, 175].

R14. Step 2.13 was added to explain in further detail: "2.13. Seal with a 12-mm diameter coverslip. Cover the opening of the PDMS well with a 12-mm diameter coverslip. Press down gently onto the coverslip with tweezers so the excess cell suspension escapes to the edge of the well. Use a tissue to remove the excess cell suspension."

Q15. Please specify the microscope and stage incubator type in the material & methods section only or explain why only this system can be used [3.1, 180-181]. Is O2 necessary for this assay to work?

R15. The commercial names of the microscope and incubator were removed from the protocol. Step 3.1 now reads, "3.1. Load microparticle array with cells on the live cell imaging station with a microscope equipped with a cage incubator set to 37 °C, 5 % CO_2, and 90 % relative humidity."

Q16. Please explain in more detail how you generate individual tracks of neutrophils using Imaris software. Do you track them manually or do you use automated tracking, and if so, which parameters/settings do you use for automated tracking? [3.2, 186-187].

R16. Step 3.3 was modified as follows:

"3.3. Use an automated cell tracking software to track the migration of individual neutrophils toward the bioparticle cluster.

3.3.1. Use the autoregression mode of a spot detection cell tracking software. Set the spot radius to 5 μm (the approximate size of a neutrophil nucleus). Set the minimum track length to 120 s and a maximum gap size of one frame.

3.3.2. From the data generated by the cell tracking software, extract the files that contain the neutrophil position and speed. These files can be used with a graphing software to generate neutrophil migration tracks (**Fig. 2C**) and a heat map of speed vs. time (**Fig. 2D**), respectively."

Q17. The generation of heat maps of speed vs. time are generated with software different to Imaris, right? [3.3, 189].

R17. We used Matlab and JMP to generate the plots in Figure 2. However, it is not important which graphing software you use to generate the plots from the Imaris data. We clarified that a separate graphing software was used to generate the plots in step 3.3.2. as follows: "3.3.2. From the data generated by the cell tracking software, extract the files that contain the neutrophil position and speed. These files can be used with a graphing software to generate neutrophil migration tracks (**Fig. 2C**) and a heat map of speed vs. time (**Fig. 2D**), respectively."

Q18. Please show in detail the steps in 3.4 to analyze the bioparticle cluster, either in video or Figure.

R18. The following analysis steps are described for the analysis of the swarms:

"3.4. Use the 405 nm fluorescent images to track swarm size over time on an image analysis software of your choice.
3.4.1. Define regions of interest (ROIs) around each bioparticle cluster where neutrophils will swarm. Keep the same size ROI to analyze each bioparticle cluster.
3.4.2. Analyze the mean fluorescent intensity of the 405-nm images within each ROI over time.
3.4.3. Generate a calibration curve of mean fluorescent intensity to swarm size by taking manual measurements at various swarm sizes from 0 μm^2 to the maximum swarm size. Use this calibration to calculate the swarm size over time."

 Q19. Do you track neutrophils inside the cluster or only their recruitment to the cluster? Fig2c only shows tracks of recruited neutrophils, but not tracks of neutrophils in the swarm. It is not clear in Fig2c, if there are tracks underneath the red circle that indicates the micropattern.

R19. We only track the recruitment of neutrophils to the cluster. When neutrophils reach the cluster, their nuclei overlap with other nuclei in the cluster. Thus, we cannot accurately track a neutrophil within the cluster. The following text was added to the Results section: "We track the migration of individual neutrophil nuclei as they migrate toward the bioparticle cluster. When neutrophils reach the bioparticle cluster, their nuclei overlap with other nuclei in the cluster. Thus, we cannot accurately track a neutrophil within the cluster."

Q20. Did you use 30-μm sized E. coli bioparticle patterns for all your experiments? Please indicate at beginning of the result section. The Table of Materials has zymosan and E. coli particles.

R20. *E. coli* and zymosan particles were used for different experiments. The following explanation was added to the results section: "Zymosan and *E. coli* bioparticle clusters both result in the generation of neutrophil swarms. For our results, **Fig. 2B** uses data from neutrophil swarms generated by *E. coli* particles. **Fig. 3** and the other panels of **Fig. 2** use neutrophil swarms generated by zymosan particles."

Q21. Please clarify the number of replicates you used in Fig2. Is n the number of different neutrophil donors, and N the number of clusters you analyzed from a total of n donors?

R21. The figure caption was modified for clarity. For **Fig. 2B**, the data comes from 32 neutrophil swarms (n) from one donor (N). The caption for Fig. 2B was modified as follows:

"ANOVA, p < 0.0001, n = 32 neutrophil swarms, N = 1 donor, error bars = standard deviation."

Q22. What does ,count' mean in Fig1D? Is this plot a representative of one experiment or does it show data from different replicates?

R22. The caption for **Fig. 2D** was edited as follows: "Each count on the heat map represents a neutrophil with the given instantaneous speed at the given time point. These heat maps are representative of 1 experiment (n = 1 swarm, N = 1 donor). (ANOVA, 6114 neutrophils (swarming), 32116 neutrophils (control), p < 0.0001)"

Q23. Please double-check if you used a cytokine microarray or a microarray that detects a range of human proteins. For example, some of the differentially regulated proteins are receptors (TLR2, IL-6R) and not cytokines [4, 203-216 and discussion].

R23. It is a microarray that detects a range of human proteins. Step 4.6. was edited as follows: "4.6. Use a microarray kit that detects a range of human proteins to process samples."

Q24. How reproducible is the identification of the proteins that you found in the supernatant of swarming neutrophils? Please include a measure of variability in Fig3.

R24. The supernatant experiment was done in triplicates for the same donor. We have added the errors bars to Figure 3. The following text was added to the **Fig. 3** caption: "(Error bars = standard deviation, n = 3 replicates, N = 1 donor)" The goal of this manuscript is to highlight the method, and how the method can enable quantification of different cytokines or proteins. In this manuscript we are not making any claims about what protein has or has not been identified.

Q25. Please refer to the cytokines that were already identified in Ref. 5 before.

R25. The following text was added to the results section. "Of the 16 proteins we identified, 12 proteins were identified by our previous publication.[5] Adipsin, galectin-3, nidogen-1, pentraxin 3, TIMP-1, and TLR2 were shown to be swarming specific, while clusterin, IL-6R, MMP-8, and MMP-9, RANK, and trappin-2 were not.[5]" The following was added to the discussion section, "Some of the proteins we identified were previously shown to be swarming specific, while others were expressed differentially by activated non-swarming neutrophils.[5]"

Q26. The authors attribute functions to proteins differentially expressed during swarming (e.g. protein is "unnecessary" if downregulated during swarming). This part is pure speculation without any proof and should be phrased more carefully (e.g. further studies are

needed to understand role of differentially regulated proteins during neutrophil swarming) [discussion, 281-287].

R26. The discussion section has been edited. The section in question now reads: "The relationship between other proteins and inflammation is less well known. The proteins that spike or decrease during swarming may be involved in the regulation of inflammation. However, further research is necessary to understand the role in inflammation of many of the proteins that are differentially expressed during swarming."

Reviewer #3:
Manuscript Summary:
Authors describe a protocol for using microarray to asses neutrophil swarming.

R. We thank the reviewer for the comments that will improve the quality of our manuscript. We have addressed all his/her comments.

Major Concerns:
The manuscript has mert; however, four major concerns should be addressed.

Q1. The introduction fails to set the stage for the need and application of the assay. A paragraph describing the research or clinical use of the assay is needed to round the paper out.

R1. The following text was added to the introduction: "In our previous publication, we demonstrated that patients with certain medical conditions (trauma, autoimmune disease, and sepsis), had neutrophils that functioned differently than healthy donors.[5] In future research studies, our platform could be used to analyze neutrophil function among a variety of patient populations. This platform can quantitively analyze the complex coordination involved in neutrophil swarming. Additional studies can be done to provide insight on the neutrophil function of a specific patient population or neutrophil response to a pathogen of interest."

Q2. An in vivo comparison with the microarray to determine the effectiveness of the assay is warranted.

R2. This manuscript describes an *in vitro* method that mimics neutrophil swarming. In the past, our method was highlighted for its accuracy by one of the world experts in the field of *in vivo* leucocyte migration imaging. The author mentions that while other *in vitro* methods "do not provide any insight into how neutrophils coordinate their dynamics and effector processes," this microarray swarming platform is a "solution for monitoring the swarming

response of human neutrophils, enabling the detailed analysis of neutrophil-derived factors released during swarming."[5] Additionally, he writes, "These microarrays in combination with live-cell imaging represent a high-throughput, standardized and precisely controlled experimental system to study neutrophil swarming."[5] Here we are describing a refined method to our original publication.[4] A comparison with an *in vivo* experiment is out of the scope of this manuscript.

Q3. The statistics fail miserably on this paper. Traditional microarray numbers are necessary including CV, standard deviation, etc. A Z' score may also be warranted.

R3. We have corrected the statistics presented in the manuscript. The following text was added to the **Fig. 3** caption: "(Error bars = standard deviation, n = 3 replicates, N = 1 donor)"

Q4. The study needs biological and technical replicates.

R4. The purpose of this manuscript is to present a refined version of our previous publication on neutrophil swarming.[4] Extensive experiments testing different conditions (e.g., biological and technical replicates) were conducted on that study.[4] We do not consider necessary the experiments suggested by the reviewer.

Minor Concerns:
None noted

Reviewer #4:
Manuscript Summary:
Neutrophils, the most abundant white blood cell in the bloodstream, are gaining attention as potential diagnostic and therapeutic targets because neutrophil activity has been attributed to a variety of medical conditions including sepsis, trauma, and cancer. This protocol describes a multistep microstamping process to generate a bioparticle microarray that stimulates precisely controlled swarming by mimicking an in vivo infection. On the microarray, neutrophils increase in speed and form stable swarms around bioparticle clusters. Significantly, they also demonstrate that secreted cytokines are differentially expressed and "spike" over the course of swarming. This in vitro swarming platform facilitates direct analysis of neutrophil migration and cytokine release in 43 a reproducible, spatially controlled manner. Neutrophil swarming is extremely important in many inflammatory diseases and plays a primary role in controlling larger pathogens such as fungi. This method is an interesting way to precisely control and quantify neutrophil swarming in vitro. This may be used to quantify "swarming" ability as a biomarker for

patient immune function in the future or as a tool to understand neutrophil communication mechanisms that facilitate efficient swarming.

R. We thank the reviewer for the comments that will improve the quality of our manuscript. We have addressed all his/her comments.

Major Concerns:

Q1. Explanation of procedure for preparing the microarray is not well explained. No description of the Zetag solution and how to prepare it.

R1. Step 1.7. and its sub steps were added to explain the preparation of the Zetag (cationic polyelectrolyte, CP) solution as follows:

"1.7. In advance, prepare a 1.6 mg/mL solution of CP in water.

1.7.1. Add the proper amount of the CP powder to water (e.g., 0.8 g to 500 mL).

1.7.2. Mix on a stir plate at room temperature overnight, or until all of the solid is dissolved into the water. The CP solution can be stored at room temperature for 6 months.

1.7.3. If desired, the CP solution can be made fluorescent by adding poly-L-lysine labelled with fluorescein isothiocyanate (PLL-FITC).

1.7.3.1. Aliquot about 10 mL of the CP solution. Add a small amount of PLL-FITC (0.05 mg, the amount can be altered to adjust the brightness of fluorescence as desired) to the aliquoted volume.

1.7.3.2. Vortex the CP solution labeled with FITC for 20 s, or until the solution is a uniform color. The solution should be a pale yellow. Protect from light and store at 4 °C for up to 1 month."

Q2. Figures 1H and 1I are not referenced in the text.

R2. A reference to **Fig. 1M** (**Fig. 1H** in the previous version) was added to step 1.16. as follows: "If the CP is tagged with FITC, the effectiveness of the stamping can be checked at this point with a fluorescent microscope at 488 nm before proceeding to step 1.17 (**Fig. 1M**)." A reference to **Fig. 1N** (**Fig. 1I** in the previous version) was added to step 1.21. as follows: "At this point, the pattern should be checked with a fluorescent microscope at 594 nm before proceeding to step 2.1 (**Fig. 1N**)."

Q3. Did not sufficiently explain bioparticles.

R3. More information regarding the bioparticles was added. In the protocol section, step 1.18. was updated as follows: "1.18. Thaw a solution of bioparticles (e.g. *E. coli* or zymosan) and dilute to 500 µg/mL in water for injection (WFI). Note: The bioparticles do not need to

be opsonized. Neutrophil surface receptors directly recognize molecules on these bioparticles.[19-21]" Additionally, the following text was added to the results section: "When neutrophils are added to the bioparticle microarray, neutrophils that come into contact with the bioparticle clusters become activated and initiate the swarming response," and "Zymosan and *E. coli* bioparticle clusters both result in the generation of neutrophil swarms. For our results, **Fig. 2B** uses data from neutrophil swarms generated by *E. coli* particles. **Fig. 3** and the other panels of **Fig. 2** use neutrophil swarms generated by zymosan particles."

Q4. Did not define quantification parameters (chemotactic index, radial velocity, speed, and total distance traveled).

R4. The results section was updated as follows: "We measured the speed (distance travelled / time) of swarming and non-activated neutrophils" The discussion was updated as follows:, "For example, we have previously shown that this platform can be used to calculate the chemotactic index (CI, the cosine of the angle between the neutrophil velocity vector and the position vector between the neutrophil and the nearest bioparticle cluster), speed (distance neutrophil travels divided by time), radial velocity (speed multiplied by CI), and total distance traveled (difference between initial and final neutrophil position) of individual migrating neutrophils.[5]"

Q5. Data generated by Imaris (step 3.3) not well explained.

R5. Step 3.3 was expanded as follows:

"3.3. Use an automated cell tracking software to track the migration of individual neutrophils toward the bioparticle cluster.

3.3.1. Use the autoregression mode of a spot detection cell tracking software. Set the spot radius to 5 µm (the approximate size of a neutrophil nucleus). Set the minimum track length to 120 s and a maximum gap size of one frame.

3.3.2. From the data generated by the cell tracking software, extract the files that contain the neutrophil position and speed. These files can be used with a graphing software to generate neutrophil migration tracks (**Fig. 2C**) and a heat map of speed vs. time (**Fig. 2D**), respectively."

Minor Concerns:
Q6. Microscopy images and protocol do not mention what magnification to use.

R6. The magnification was added to step 3.2. of the protocol as follows: "Use time-lapse fluorescent and brightfield microscopy to record images at 10x magnification every 10 seconds at 405 nm, 594 nm, and brightfield."

Q7. Videos do not have captions or scale bars.

R7. Scale bars have been added to the videos. Captions have been added to the videos as follows:

"**Video S1. Neutrophil swarming toward zymosan bioparticle clusters.** Neutrophil nuclei are shown in blue. Zymosan targets are marked with red circles. Scale bar: 50 µm. Original acquisition time: 60 min.

Video S2. Non-activated neutrophil random migration. Neutrophil nuclei are shown in blue. Scale bar: 50 µm. Original acquisition time: 60 min.

Q8. Some typos/copy editing issues.

R8. We thank the reviewer for this comment. We have reread the manuscript and made several edits.

Reviewer #5:
Manuscript Summary:
The manuscript describes the steps for manufacturing an assay for neutrophil swarming and the protocols for testing human neutrophil swarming function.

R. We thank the reviewer for the comments that will improve the quality of our manuscript. We have addressed all his/her comments.

Major Concerns:
Q1. A procedure for verifying the accuracy of stamping after step 1.15 should be included in the protocol. Similarly, after step 1.20, a procedure should be described for verifying that the beads are just on the spots and not on the rest of the glass surface.

R1. The following was added to step 1.16: "If the CP is tagged with FITC, the effectiveness of the stamping can be checked at this point with a fluorescent microscope at 488 nm before proceeding to step 1.17 (**Fig. 1M**)." The following was added to step 1.21: "At this point, the pattern should be checked with a fluorescent microscope at 594 nm before proceeding to step 2.1 (**Fig. 1N**)."

Q2. The procedure for Image analysis is overly simplified and all steps should be described in detail. Screen captures should be used to document the steps and their effect on the analysis.

R2. The procedure for image analysis was expanded as follows:

"3.3. Use an automated cell tracking software to track the migration of individual neutrophils toward the bioparticle cluster.

3.3.1. Use the autoregression mode of a spot detection cell tracking software. Set the spot radius to 5 μm (the approximate size of a neutrophil nucleus). Set the minimum track length to 120 s and a maximum gap size of one frame.

3.3.2. From the data generated by the cell tracking software, extract the files that contain the neutrophil position and speed. These files can be used with a graphing software to generate neutrophil migration tracks (**Fig. 2C**) and a heat map of speed vs. time (**Fig. 2D**), respectively.

3.4. Use the 405 nm fluorescent images to track swarm size over time on an image analysis software of your choice.

3.4.1. Define regions of interest (ROIs) around each bioparticle cluster that encompasses the largest swarm size. Keep the same size ROI to analyze each bioparticle cluster.

3.4.2. Analyze the mean fluorescent intensity of the 405-nm images within each ROI over time.

3.4.3. Generate a calibration curve of mean fluorescent intensity to swarm size by taking manual measurements at various swarm sizes from 0 μm^2 to the maximum swarm size. Use this calibration to calculate the swarm size over time."

Q3. The procedure for using the cytokine array panel from Raybiotech is missing from the manuscript. This is important and the steps should be described in detail.

R3. Step 4.6. was expanded in the protocol section as follows:

"4.6. Use a microarray kit that detects a range of human proteins to process samples.

4.6.1. Add 200 μL of each sample to a separate dialysis tube (provided with kit).

4.6.2. Place dialysis tubes in a beaker containing at least 500 mL phosphate buffered saline (PBS, pH = 8.0). Stir gently on a stir plate for at least 3 h at 4 °C. Exchange PBS in beaker and repeat this step.

4.6.3. Transfer each sample to a clean centrifuge tube and centrifuge at 9,000 x g for 5 min to remove any precipitates. Transfer each supernatant to a clean tube.

4.6.4. Biotinylate each sample by adding 36 μL of 1X labeling reagent kit (provided with kit) per mg of total protein in dialyzed sample to 180 μL of dialyzed sample. Incubate at 20 °C for 30 min. Mix gently every 5 min.

4.6.5. Add 3 µL of Stop Solution (provided with kit) into each sample tube. Transfer each sample to a fresh dialysis tube and repeat steps 4.6.2 – 4.6.3. At this stage, the sample can be stored at -20 °C or -80 °C until you are ready to proceed.

4.6.6. Allow glass slide (provided with kit, stored at -20 °C) to come to room temperature. Place assembled glass slide in a laminar flow hood for 1 – 2 h at room temperature.

4.6.7. Add 400 µL of Blocking Buffer (provided with kit) into each well of assembled glass slide. Incubate at room temperature for 30 min.

4.6.8. Centrifuge prepared samples for 5 min at 9,000 x g to remove precipitates or particulates. Dilute 5x with Blocking Buffer.

4.6.9. Remove Blocking Buffer from each well. Add 400 µL of diluted samples into appropriate wells. Incubate for 2 h at room temperature while rocking.

4.6.10. Decant samples from each well. Wash 3x with 800 µL 1X Wash Buffer I (provided with kit) at room temperature for 5 min each while rocking.

4.6.11. In a clean container, submerge assembled glass slide in 1X Wash Buffer I. Wash 2x at room temperature for 5 min each while rocking.

4.6.12. Add 400 µL of 1X Cy3-Conjugated Streptavidin to each sub-array. Cover with plastic adhesive strips. Protect from light for the remainder of the protocol.

4.6.13. Incubate for 2 h at room temperature while rocking.

4.6.14. Decant solution and disassemble glass slide from the sample chambers.

4.6.15. In a 30 mL centrifuge tube (provided with kit), carefully add glass slide and enough 1X Wash Buffer I to cover the glass slide. Wash 3x for 10 min each at room temperature while rocking.

4.6.16. In the 30 mL centrifuge tube, wash 2x with 1X Wash Buffer II for 5 min each at room temperature while rocking.

4.6.17. Wash glass slide with 30 mL ddH$_2$O for 5 min. Remove the glass slide from the centrifuge tube and allow to dry for 20 min in a laminar flow hood. The prepared glass slide may be stored at -20 °C until ready to scan.

4.6.18. Scan the glass slide with a microarray scanner at a fluorescence emission of 555 nm."

Minor Concerns:
Q4. The manuscript needs careful editing. Several sentences are difficult to understand. On page 2 "neutrophil activity has been attributed to a variety of medical conditions" does not

make sense. The "two-layer process" in the second paragraph is confusing. I suppose a "two-step process" was more appropriate.

R4. We thank the reviewer for this comment. We have reread the manuscript and made several edits. For example, the first sentence in the introduction now reads, "Neutrophils, the most abundant white blood cell in the bloodstream,[1] are gaining attention as potential diagnostic and therapeutic targets[2, 3] because neutrophils may be involved in a variety of medical conditions including gout,[4] sepsis,[3] trauma,[5, 6] cancer,[1, 7, 8] and various autoimmune diseases.[5, 9]" Additionally, the noted sentence in the second paragraph has been changed to, "We generate bioparticle microarrays on glass slides in a two-step process."

References

1.   Thomas, C.J., Schroder, K. Pattern recognition receptor function in neutrophils. *Trends in Immunology*. **34** (7), 317–328, doi: 10.1016/j.it.2013.02.008 (2013).

2.   Underhill, D.M., Ozinsky, A. Toll-like receptors: Key mediators of microbe detection. *Current Opinion in Immunology*. **14** (1), 103–110, doi: 10.1016/S0952-7915(01)00304-1 (2002).

3.   Netea, M.G., Van Der Meer, J.W.M., Kullberg, B.J. Recognition of fungal pathogens by toll-like receptors. *Immunology of Fungal Infections*. 259–272, doi: 10.1007/1-4020-5492-0_11 (2007).

4.   Reátegui, E. *et al.* Microscale arrays for the profiling of start and stop signals coordinating human-neutrophil swarming. *Nature Biomedical Engineering*. **1** (7), 1–12, doi: 10.1038/s41551-017-0094 (2017).

5.   Lämmermann, T. Cell migration: Arraying neutrophils in swarms. *Nature Biomedical Engineering*. **1** (7), 1–2, doi: 10.1038/s41551-017-0100 (2017).